Visualize how your peptide clears from the body — half-life, steady state, and accumulation for every injection schedule.
Half-Life
~3 h
Time for 50 % to be eliminated
Steady State
~12 h
≈ 4.3 half-lives
Accumulation
×1.00
Cmax at steady state ÷ Cmax first dose
Gone After
~19 h
after last dose
Source: Vyleesi US Prescribing Information, section 12.3 (terminal half-life). Research tool. Uses a simplified first-order elimination model and normalizes concentration to % of peak. Not a medical or dosing recommendation. PT-141: ~2.7 h.
Official prescribing information for the finished Vyleesi solution reports a mean terminal plasma half-life of approximately 2.7 hours, with a 1.9 to 4.0 hour range.
The value belongs to that subcutaneous finished formulation and study context. It is not a preparation or scheduling instruction for this lyophilized research vial.
DailyMed Vyleesi prescribing information: mean terminal half-life approximately 2.7 hours.
PT-141, commonly called bremelanotide, is a synthetic cyclic heptapeptide developed from melanocortin peptide research. Its compact seven-amino-acid structure and activity across melanocortin receptor subtypes make it a defined reference material for receptor pharmacology, analytical method development, and other controlled laboratory investigations. This product contains 10 mg of lyophilized PT-141 in a sealed research vial.
The vial is supplied exclusively for research use. It is not a medicine, medical device, compounded preparation, or material intended for administration to people or animals. The 10 mg label describes the nominal research-vial format; it is not a recommended dose and must not be interpreted as clinical guidance.
For research use only. Not for human or veterinary use, diagnosis, treatment, prevention, or consumption. The presence of bremelanotide as the active peptide in an approved medicine does not make this research vial an approved, substitutable, or clinically validated product.